Clozapine prescribing during follow-up of a first-episode psychosis cohort
Introduction Of those with schizophrenia, one third develop treatment-resistant illness. Nearly 60% of these benefit from clozapine- the only antipsychotic medication licensed in this group. Objectives As treatment-resistant illness developed in the follow-up of a first-episode psychosis (FEP) c...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2021-04-01
|
Series: | European Psychiatry |
Subjects: | |
Online Access: | https://www.cambridge.org/core/product/identifier/S0924933821021246/type/journal_article |